Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026

Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.

Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.

The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.

Avadel Pharmaceuticals plc
Avadel Pharmaceuticals logo
CountryIreland
Founded2015
IPO DateJun 7, 1996
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees188
CEOGregory Divis

Contact Details

Address:
10 Earlsfort Terrace
Dublin, D02 T380
Ireland
Phone353 1 901 5201
Websiteavadel.com

Stock Details

Ticker SymbolAVDL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001012477
CUSIP Number05337M104
ISIN NumberIE00BDGMC594
SIC Code2834

Key Executives

NamePosition
Gregory J. Divis Jr.Chief Executive Officer and Director
Thomas S. McHughSenior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer
Jerad G. SeurerGeneral Counsel, Company Secretary and Compliance Officer
Susan RodriguezChief Operating Officer
Gregory J. DavisVice President of Corporate and Business Development
Angie WoodsVice President of People and Culture
Dr. Jason M. Vaughn Ph.D., R.Ph.Senior Vice President of Technical Operations
Jennifer Gudeman PharmDSenior Vice President of Medical and Clinical Affairs
Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D.Chief Business Officer
Marla Scarola M.S.Senior Vice President of Regulatory and Quality

Latest SEC Filings

DateTypeTitle
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Feb 12, 2026POS AMPost-Effective amendments for registration statement
Feb 12, 2026POS AMPost-Effective amendments for registration statement